SCHEMBL13199232

SCHEMBL13199232

O=C(Cc1cccc(O)c1)NNC(=O)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.55
KDM4E B2RXH2 5/20 0.51
HTT P42858 4/20 0.51
LMNA P02545 1/20 0.51
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
POLB P06746 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PLAU P00749 1/20 0.50
ELANE P08246 1/20 0.50
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
GAA P10253 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199110 0.90 KDM4E (0.55) KDM4EHTTALDH1A1KMT2AMEN1
SCHEMBL13199235 0.87 KDM4E (0.50) NLRP3KDM4EHTTALDH1A1KMT2A
SCHEMBL13199164 0.87 KMT2A (0.60) NLRP3KDM4EHTTALDH1A1KMT2A
SCHEMBL13199231 0.87 TDP1 (0.62) KDM4EHTTLMNAALDH1A1KMT2A
SCHEMBL13199195 0.86 ALDH1A1 (0.58) KDM4EHTTALDH1A1KMT2AMEN1
SCHEMBL13199160 0.86 TDP1 (0.55) NLRP3KDM4EHTTLMNAALDH1A1
SCHEMBL13199178 0.86 NPC1 (0.55) NLRP3KDM4EHTTALDH1A1KMT2A
SCHEMBL13199129 0.85 ALDH1A1 (0.57) NLRP3KDM4EHTTLMNAALDH1A1
SCHEMBL13199261 0.85 CA2 (0.50) NLRP3KDM4EHTTALDH1A1KMT2A
SCHEMBL14098304 0.84 KMT2A (0.57) NLRP3KDM4EHTTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 NLRP3 3060/4885KDM4E 1312/4885HTT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.